Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Esther H.M. van Egmond"'
Autor:
Marleen M. van Loenen, Renate de Boer, Renate S. Hagedoorn, Esther H.M. van Egmond, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk
Publikováno v:
Haematologica, Vol 96, Iss 3 (2011)
To broaden the applicability of adoptive T-cell therapy for the treatment of hematologic malignancies, we aim to start a clinical trial using HA-1-TCR transferred virus-specific T cells. TCRs directed against the minor histocompatibility antigen (MiH
Externí odkaz:
https://doaj.org/article/a1e3149ea0b74dcfa916da61ec8bc630
Autor:
Marieke Griffioen, Esther H.M. van Egmond, Michel G.D. Kester, Roel Willemze, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk
Publikováno v:
Haematologica, Vol 94, Iss 9 (2009)
The aim of adoptive T-cell therapy of cancer is to selectively confer immunity against tumor cells. Autoimmune side effects, however, remain a risk, emphasizing the relevance of a suicide mechanism allowing in vivo elimination of infused T cells. We
Externí odkaz:
https://doaj.org/article/c59a77c43b734b6dbea72f0e4c1cf614
Autor:
Eva A.S. Koster, Peter A. von dem Borne, Peter van Balen, Esther H.M. van Egmond, Erik W.A. Marijt, Sabrina A.J. Veld, Inge Jedema, Tjeerd J.F. Snijders, Daniëlle van Lammeren, Hendrik Veelken, J.H. Frederik Falkenburg, Liesbeth C. de Wreede, Constantijn J.M. Halkes
Publikováno v:
Transplantation and Cellular Therapy. 29:268.e1-268.e10
After allogeneic stem cell transplantation (alloSCT), patient-derived stem cells that survived the pre-transplant conditioning compete with engrafting donor stem cells for bone marrow (BM) repopulation. In addition, donor-derived alloreactive T-cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d209ea66f6e3899fddb9c3e2e387da7c
https://doi.org/10.1016/j.jtct.2022.12.022
https://doi.org/10.1016/j.jtct.2022.12.022
Autor:
Marthe C.J. Roex, Lisette Bogers, Esther H.M. van Egmond, Jaap Jan Zwaginga, Tanja Netelenbos, Peter A. von dem Borne, Sabrina A.J. Veld, Inge Jedema, Hendrik Veelken, Charissa Wijnands, Constantijn J.M. Halkes, J.H. Frederik Falkenburg
Publikováno v:
Cytotherapy, 23(1), 46-56. ELSEVIER SCI LTD
Background aims: To reduce the risk of graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloSCT), T-cell depletion (TCD) of grafts can be performed by the addition of alemtuzumab (ALT) "to the bag" (in vitro) before transp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37449492cb55a877d68f5e44f3c946df
https://doi.org/10.1016/j.jcyt.2020.08.003
https://doi.org/10.1016/j.jcyt.2020.08.003
Autor:
Lothar Germeroth, Inge Jedema, Conny Hoogstraten, Christian Stemberger, Marthe C.J. Roex, Lois Hageman, Sabrina A.J. Veld, J.H. Frederik Falkenburg, Hermann Einsele, Esther H.M. van Egmond
Publikováno v:
Blood, 136(4), 455-467. AMER SOC HEMATOLOGY
Tumor-associated antigens (TAAs) are monomorphic self-antigens that are proposed as targets for immunotherapeutic approaches to treat malignancies. We investigated whether T cells with sufficient avidity to recognize naturally overexpressed self-anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9a15da09ebee06df9c334687579c74
https://hdl.handle.net/1887/3185135
https://hdl.handle.net/1887/3185135
Autor:
Hermann Einsele, Peter van Balen, Lothar Germeroth, Ann C. T. M. Vossen, M Ron Schaafsma, Lois Hageman, Marthe C.J. Roex, Jaap Jan Zwaginga, Sabrina A.J. Veld, Conny Hoogstraten, Constantijn J.M. Halkes, Inge Jedema, Esther H.M. van Egmond, Hendrik Veelken, Liesbeth C. de Wreede, Sophia Danhof, J.H. Frederik Falkenburg, Ellis van Liempt, Pauline Meij
Publikováno v:
Leukemia, 34(3), 831-844. NATURE PUBLISHING GROUP
Prophylactic infusion of selected donor T cells can be an effective method to restore specific immunity after T-cell-depleted allogeneic stem cell transplantation (TCD-alloSCT). In this phase I/II study, we aimed to reduce the risk of viral complicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6780fd6670d1428463c47c68fb08c168
https://hdl.handle.net/1887/3181179
https://hdl.handle.net/1887/3181179
Autor:
Esther H.M. van Egmond, Xiaohang Qiao, Sabrina A.J. Veld, Inge Jedema, Wilhelmina G. M. Kroes, Jacques Neefjes, Marieke Griffioen, Kevin Rijs, Constantijn J.M. Halkes, Willem H. Zoutman, J.H. Frederik Falkenburg, Floris C. Loeff, Maarten H. Vermeer
Publikováno v:
American Journal of Hematology, 94(1), 93-102
American Journal of Hematology
American Journal of Hematology
Adult B‐lymphoblastic leukemia (B‐ALL) is a hematological malignancy characterized by genetic heterogeneity. Despite successful remission induction with classical chemotherapeutics and novel targeted agents, enduring remission is often hampered b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a815ef9a1d31ccfd96ff46120d1242ea
https://hdl.handle.net/1887/88087
https://hdl.handle.net/1887/88087
Autor:
Ellis van Liempt, Lothar Germeroth, Conny Hoogstraten, Esther H.M. van Egmond, Inge Jedema, Hermann Einsele, Sabrina A.J. Veld, J.H. Frederik Falkenburg, Peter van Balen, Hendrik Veelken, Liesbeth C. de Wreede, Jaap Jan Zwaginga, Marthe C.J. Roex, Constantijn J.M. Halkes, Lois Hageman
Viral infections and disease relapses are major complications between T cell depleted allogeneic stem cell transplantation (TCD alloSCT) and donor lymphocyte infusion (DLI). The prophylactic infusion of selected donor T cells may be an effective meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::debd3c5abf67a26f93f605bb665223a3
https://hdl.handle.net/1887/121191
https://hdl.handle.net/1887/121191
Autor:
Renate S. Hagedoorn, J.H. Frederik Falkenburg, Renate de Boer, Marleen M. van Loenen, Esther H.M. van Egmond, Mirjam H.M. Heemskerk
Publikováno v:
Journal of Immunotherapy. 34:165-174
To broaden the applicability of cellular immunotherapy, adoptive transfer of T-cell receptor (TCR) transferred T cells may be an attractive strategy. Using this approach, high numbers of defined antigen-specific T cells can be engineered. As the intr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729993501a61718723bf5609a3b67948
https://doi.org/10.1097/cji.0b013e318206a10c
https://doi.org/10.1097/cji.0b013e318206a10c
Autor:
J.H. Frederik Falkenburg, Esther H.M. van Egmond, Michel G.D. Kester, Mirjam H.M. Heemskerk, Marieke Griffioen, Roel Willemze
Publikováno v:
Haematologica. 94:1316-1320
The aim of adoptive T-cell therapy of cancer is to selectively confer immunity against tumor cells. Autoimmune side effects, however, remain a risk, emphasizing the relevance of a suicide mechanism allowing in vivo elimination of infused T cells. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb045150d1f663c7ffb59a05f5fee31
https://doi.org/10.3324/haematol.2008.001677
https://doi.org/10.3324/haematol.2008.001677